In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $30.00. The company’s shares closed yesterday at $27.19.
According to TipRanks, Schott is a 3-star analyst with an average return of 2.1% and a 52.59% success rate. Schott covers the Healthcare sector, focusing on stocks such as Pfizer, Gilead Sciences, and Idexx Laboratories.
In addition to J.P. Morgan, Pfizer also received a Hold from Citi’s Andrew Baum in a report issued on March 4. However, on the same day, Cantor Fitzgerald maintained a Buy rating on Pfizer (NYSE: PFE).
See the top stocks recommended by analysts >>
The company has a one-year high of $40.15 and a one-year low of $25.38. Currently, Pfizer has an average volume of 48.27M.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer (PFE) Company Description:
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
